Careers  |  Sign In  |  Register

Immunotherapy Plus Targeted Drug in First-Line Kidney Cancer


Interim results from the preliminary analysis of the JAVELIN-Renal 101 trial suggest that adding immunotherapy to a targeted agent appears to significantly improve progression-free survival (PFS) when compared with a targeted agent alone in the first-line treatment of advanced renal cell carcinoma (RCC). The data also indicated the objective response rate of avelumab plus axitinib may be more than twice what was observed with sunitinib.

Learn more by clicking here.